Kai-Xuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kai-Xuan Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jianguo Hong
Department of General Surgery, Qilu hospital, Shandong University, Jinan, China
2 shared publications - Lun-Jie Yan
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China
2 shared publications - Tao Li
Department of General Surgery, QiLu Hospital, Shandong University, Jinan, Shandong, China
2 shared publications - Zhao-Ru Dong
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China
2 shared publications - Chuncheng Yang
Institute of Basalt Fiber Materials and School of Gemology and Materials Science, Hebei GEO University, Shijiazhuang, China
1 shared publication - Guang-Xiao Meng
Department of General Surgery, QiLu Hospital, Shandong University, Jinan, Shandong, China
1 shared publication
Latest Publications
- Open Access
- 17 January 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (5) , 835-846
Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis
Previous meta-analyses have shown that aspirin use may reduce the risk of hepatocellular carcinoma (HCC). However, the optimal dose, frequency, and duration of aspirin use or the safety and efficacy of aspirin in target populations for HCC prevention remain unclear. The study aim was to investigate the efficacy and safety of aspirin for prevention of HCC.
- 17 January 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (5) , 835-846
Open AccessEfficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis
Previous meta-analyses have shown that aspirin use may reduce the risk of hepatocellular carcinoma (HCC). However, the optimal dose, frequency, and duration of aspirin use or the safety and efficacy of aspirin in target populations for HCC prevention remain unclear. The study aim was to investigate the efficacy and safety of aspirin for prevention of HCC.
- Open Access
- 19 February 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
Background and Aims: The clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the effect of antiviral treatment prophylaxis on HBV reactivation, overall survival (OS), and postoperative liver function in patients with low preoperative HBV-DNA levels undergoing curative resection.Methods: A meta-analysis was conducted by searching Web of Science, PubMed, Embase, and Cochrane Library until May 2020. We used REVMAN for data analysis and completed the study under the PRISMA guidelines.Results: Three randomized trials and seven cohort studies, comprising of 1,131 individuals, were included in the meta-analysis. Antiviral treatment significantly reduced the rate of HBV reactivation after curative treatment of HCC, with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21; P < 0.00001). The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74; P = 0.0002) in respect of OS rate. However, by pooling the data from studies that reported ALT on the 30th day postoperatively, the result didn’t reach statistical significance (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36). The I² values of the heterogeneity test for the above three comparisons are zero.Conclusion: Antiviral therapy during curative resection is effective in reducing HBV reactivation and improving OS rate in HCC patients with low viral load.
- 19 February 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessClinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
Background and Aims: The clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the effect of antiviral treatment prophylaxis on HBV reactivation, overall survival (OS), and postoperative liver function in patients with low preoperative HBV-DNA levels undergoing curative resection.Methods: A meta-analysis was conducted by searching Web of Science, PubMed, Embase, and Cochrane Library until May 2020. We used REVMAN for data analysis and completed the study under the PRISMA guidelines.Results: Three randomized trials and seven cohort studies, comprising of 1,131 individuals, were included in the meta-analysis. Antiviral treatment significantly reduced the rate of HBV reactivation after curative treatment of HCC, with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21; P < 0.00001). The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74; P = 0.0002) in respect of OS rate. However, by pooling the data from studies that reported ALT on the 30th day postoperatively, the result didn’t reach statistical significance (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36). The I² values of the heterogeneity test for the above three comparisons are zero.Conclusion: Antiviral therapy during curative resection is effective in reducing HBV reactivation and improving OS rate in HCC patients with low viral load.